相关实验视频

Updated: Sep 11, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

免疫检查点抑制剂在复发性/耐药性霍奇金淋巴瘤中重新挑战的结果

Yoshito Nishimura¹, Yiqun Han², Nadia Toumeh³

¹Division of Hematology, Mayo Clinic, Rochester, MN.

Blood neoplasia

|August 14, 2025

概括

在停止治疗后,使用免疫检查点抑制剂 (ICI) 挑战复发/耐药霍奇金淋巴瘤患者的复发会产生高反应率. 这种策略提供了持久的缓解和可接受的安全性,使其成为一个可行的治疗选择.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

免疫检查点抑制剂 (ICI) 已经改变了复发性/耐药性 (R/R) 霍奇金淋巴瘤 (HL) 的治疗.
由于初始反应或免疫相关不良事件 (AE),患者可能会停止ICI治疗.
在R/R HL中先前停止治疗后重新引入ICI (ICI重新挑战) 的疗效和安全性尚未得到充分证实.

研究的目的:

系统地评估免疫检查点抑制剂 (ICI) 在复发/耐药 (R/R) 霍奇金淋巴瘤 (HL) 患者的疗效和安全性.

主要方法:

按照PRISMA的指导方针,进行了系统的文献搜索,直到2025年1月10日.
包括报告R/R HL患者ICI再挑战结果的研究.
关于整体响应率 (ORR),完整响应率 (CR),无进展生存期 (PFS) 和与治疗相关的副作用的数据被提取和汇总.

主要成果:

该分析包括来自17项研究的207名患者.
综合总体应答率 (ORR) 为63% (95% CI, 55-70),完全应答率 (CR) 为43% (95% CI, 35-52).
复发后无进展生存 (PFS) 的中位数为13.3个月 (95% CI,7.9-18.8),任何级别/严重的副作用发生在47%/31%的患者中.

结论:

在复发性/耐药性 (R/R) 经典霍奇金淋巴瘤 (HL) 中,免疫检查点抑制剂 (ICI) 重新挑战显示出高响应率和持久缓解.
ICI重试的安全性概况是可以接受的,并且与不间断的ICI治疗相美.
ICI重新挑战代表了R/R HL的潜在可行的治疗策略,需要仔细选择和监测患者.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...